Clinical trials · Maryland
B Cell Malignancies clinical trials in Maryland
We’re tracking 45 recruiting b cell malignancies studies with a site in Maryland — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Bethesda, MarylandAges 18 years+ - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Bethesda, MarylandAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
New treatment for blood cancers that have returned
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
Bethesda, MarylandAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Baltimore, MarylandAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Bethesda, MarylandAges 18 years+ - NCT04139304RecruitingEarly Phase 1
Study of daratumumab with EPOCH for plasmablastic lymphoma
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Baltimore, MarylandAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Baltimore, MarylandAges 18 years+ - NCT02473757Enrolling by invitation
Follow-up program for adults previously treated with CAR T
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Bethesda, MarylandAges 18 years+ - NCT05170399RecruitingPhase 4
Testing how cancer vaccines work in B-cell blood cancers
This study measures how well certain vaccines stimulate the immune system in people with B-cell blood cancers such as CLL and different types of lymphoma or Waldenström macroglobulinemia. It may help doctors better predict who will benefit most from vaccination and improve vaccine planning for these conditions.
Bethesda, MarylandAges 18–90 - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Baltimore, MarylandAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Baltimore, MarylandAges 18 years+ - NCT03666000RecruitingPhase 1
Azer-cel for B-cell lymphoma and leukemia that has returned
This trial tests an investigational cell therapy called Azer-cel for people with certain types of blood cancer (non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia) that has come back or not responded to previous treatments. The therapy uses your own immune cells that have been modified to find and attack cancer cells.
Baltimore, MarylandAges 18 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Baltimore, MarylandAges Up to 26 years - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Baltimore, MarylandAges 18 years+ - NCT04989803RecruitingPhase 1/Phase 2
Tested two lymphoma cell therapies for relapsed or resistant cancer
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
Baltimore, MarylandAges 18 years+ - NCT07648264RecruitingPhase 3
Immune Boost Treatment After CAR-T or TCE Therapy
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
Baltimore, MarylandAges 18 years+ - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Baltimore, MarylandAges 6 months–30 years - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Baltimore, MarylandAges 18 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Baltimore, MarylandAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bethesda, MarylandAges 18 years+
B Cell Malignancies trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting b cell malignancies studies listed above.
- National Institutes of Health Clinical Center · 7 studies
- Johns Hopkins University · 3 studies
- University of Maryland, Baltimore · 3 studies
- University of Maryland · 2 studies
- American Oncology Partners
- Center for Cancer and Blood Disorders
- Frederick Health - James M Stockman Cancer Institute
- GC2202 Study Site 111
What taking part in a b cell malignancies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
B Cell Malignancies trials in other states
Common questions
- Are there b cell malignancies clinical trials in Maryland?
- Yes. We're currently tracking 45 recruiting b cell malignancies studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a b cell malignancies study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a b cell malignancies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New b cell malignancies studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.